DF/HCC SPORE in Prostate Cancer

这份申请是达纳-法伯/哈佛癌症中心前列腺癌项目(DF/HCC)前列腺癌专业卓越研究计划(SPORT)的修订后的重新提交申请。自2002年以来，DF/HCC前列腺癌孢子已经获得了两个周期的资助。DF/HCC由以下机构组成：达纳-法伯癌症研究所、哈佛医学院、哈佛公共卫生学院、贝丝·以色列-女执事医疗中心、布里格姆妇女医院、马萨诸塞州总医院和波士顿儿童医院。除了DF/CC的机构外，布罗德研究所和麻省理工学院也是这笔赠款的合作机构。DF/HCC前列腺癌孢子在DFCI有其管理基础。菲利普·坎托夫博士自DF/HCC前列腺癌项目和孢子项目成立以来一直领导该项目，联合董事威廉·哈恩博士(DFCI的实验室科学家)和史蒂文·巴尔克博士(BIDMC的实验室科学家)加入了他的行列。坎托夫博士直接向DF/HCC主任兼DFCI总裁爱德华·本茨博士汇报工作。DF/HCC前列腺癌孢子拥有广泛而深厚的人才基础，并有广泛的机构承诺。我们利用了大量的患者群体和尖端技术，这些技术是DF/HCC的一部分。我们提出了4个项目，解决前列腺癌的关键问题，并包含翻译部分，包括1)了解肥胖影响前列腺癌死亡率的机制2)剖析Gleason 7前列腺癌的临床异质性3)了解基因组变化在抵抗原发雄激素剥夺治疗和侵袭性前列腺癌中的作用，最后4)了解雄激素受体在去势抵抗疾病中的抵抗机制。这四个项目得到三个核心的支持--一个行政核心、一个生物统计和计算生物学核心以及一个组织和病理学核心。我们还有一个非常成功的职业发展计划，它挑选有才华的内科科学家并指导他们走向独立，以及一个开发项目计划，它为未来的孢子产生新的想法。

This application represents a revised resubmission application for a Specialized Program of Research Excellence (SPORE) in Prostate Cancer from the Prostate Cancer Program of Dana-Farber/Harvard Cancer Center (DF/HCC). The DF/HCC Prostate Cancer SPORE has been funded for two cycles since 2002. DF/HCC is comprised of the following institutions: Dana-Farber Cancer Institute; Harvard Medical School; Harvard School of Public Health; Beth Israel-Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; and Children's Hospital of Boston. In addition to the institutions in the DF/HCC, the Broad Institute and Massachusetts Institute of Technology are collaborating institutions in this grant. The DF/HCC Prostate Cancer SPORE has its administrative base at the DFCI. Dr. Philip Kantoff, who has led the DF/HCC Prostate Cancer Program and SPORE since their inception, is joined by Co-Directors Dr. William Hahn, a laboratory scientist at DFCI, and Dr. Steven Balk, a laboratory scientist at BIDMC. Dr. Kantoff reports directly to Dr. Edward Benz, Director of DF/HCC and President of DFCI. The DF/HCC Prostate Cancer SPORE has a broad and deep talent base and there is extensive institutional commitment. We take advantage of a large patient population and cutting edge technologies that are available to us as part of DF/HCC. We propose 4 Projects which address critical problems in prostate cancer and have translational components including 1) understanding the mechanism by which obesity impacts prostate cancer mortality 2) dissecting the clinical heterogeneity of Gleason 7 prostate cancer 3) understanding the role that genomic change has on resistance to primary androgen deprivation therapy and on aggressive prostate cancer and finally 4) understanding the androgen receptor based mechanisms of resistance in castration resistant disease. The four projects are supported by three Cores - an Administrative Core, a Biostatistics and Computational Biology Core, and a Tissue and Pathology Core. We also have a highly successful Career Development Program that selects talented physician scientists and mentors them to independence as well as a Developmental Projects Program that generates new ideas for the SPORE in the future.